Merck & Co., Inc. $MRK Stake Raised by Revolve Wealth Partners LLC

Revolve Wealth Partners LLC boosted its position in Merck & Co., Inc. (NYSE:MRK) by 4.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,642 shares of the company’s stock after purchasing an additional 178 shares during the period. Revolve Wealth Partners LLC’s holdings in Merck & Co., Inc. were worth $367,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Little House Capital LLC lifted its position in Merck & Co., Inc. by 1.2% in the second quarter. Little House Capital LLC now owns 25,236 shares of the company’s stock worth $1,998,000 after purchasing an additional 308 shares during the period. Semus Wealth Partners LLC lifted its position in Merck & Co., Inc. by 8.2% in the first quarter. Semus Wealth Partners LLC now owns 5,039 shares of the company’s stock worth $452,000 after purchasing an additional 382 shares during the period. Longfellow Investment Management Co. LLC lifted its position in Merck & Co., Inc. by 20.4% in the first quarter. Longfellow Investment Management Co. LLC now owns 19,376 shares of the company’s stock worth $1,739,000 after purchasing an additional 3,282 shares during the period. Quilter Plc lifted its position in Merck & Co., Inc. by 5.6% in the first quarter. Quilter Plc now owns 1,180,797 shares of the company’s stock worth $105,988,000 after purchasing an additional 62,933 shares during the period. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH lifted its position in Merck & Co., Inc. by 9.8% in the second quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 888,415 shares of the company’s stock worth $70,327,000 after purchasing an additional 79,529 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $85.64 on Tuesday. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $111.58. The stock has a fifty day moving average of $83.58 and a 200-day moving average of $81.40. The company has a market capitalization of $213.90 billion, a PE ratio of 13.19, a price-to-earnings-growth ratio of 0.88 and a beta of 0.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, beating analysts’ consensus estimates of $2.03 by $0.10. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The company had revenue of $15.81 billion during the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, October 7th. Shareholders of record on Monday, September 15th were paid a dividend of $0.81 per share. This represents a $3.24 annualized dividend and a yield of 3.8%. The ex-dividend date of this dividend was Monday, September 15th. Merck & Co., Inc.’s payout ratio is 49.92%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MRK. Weiss Ratings restated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research report on Wednesday, October 8th. Berenberg Bank downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and cut their target price for the stock from $100.00 to $90.00 in a research report on Wednesday, September 17th. Wells Fargo & Company cut their target price on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 30th. Morgan Stanley cut their price objective on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a research report on Thursday, July 10th. Finally, Citigroup assumed coverage on Merck & Co., Inc. in a research report on Monday. They set a “neutral” rating and a $95.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $105.00.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.